Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
AuthorChauhan, V. P.
Martin, J. D.
Lacorre, D. A.
Jain, S. R.
Kozin, S. V.
Mousa, A. S.
Bawendi, M. G.
Jain, R. K.
Google Scholar check
MetadataShow full item record
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors-inexpensive drugs with decades of safe use-could be rapidly repurposed as cancer therapeutics. © 2013 Macmillan Publishers Limited.
Showing items related by title, author, creator and subject.
Savva, Isavella; Pierides, Alkis M.; Constantinou-Deltas, Constantinos D. (2016)Alport syndrome (AS) is a hereditary progressive glomerulonephritis with a high life-time risk for end-stage renal disease (ESRD). Most patients will reach ESRD before the age of 30 years, while a subset of them with milder ...
Alport syndrome from bench to bedside: The potential of current treatment beyond RAAS blockade and the horizon of future therapies Gross, O.; Perin, L.; Constantinou-Deltas, Constantinos D. (2014)The hereditary type IV collagen disease Alport syndrome (AS) always leads to end-stage renal failure. Yesterday, for the past 90 years, this course was described as 'inevitable'. Today, RAAS blockade has changed the ...
On 'Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations' Voskarides, Konstantinos; Pierides, Alkis M.; Constantinou-Deltas, Constantinos D. (2013)